Recombinant Mouse Apolipoprotein A-I Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-0241

Recombinant Mouse Apolipoprotein A-I Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-0241
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Mouse
Accession Q00623
Synonym 1-Sep, 2-Sep, 42248, 42249, Alp-1, apo-AI, Apoa-1, apoA-I, Brp-14, Ltw-1, Lvtw-1
Background Apolipoprotein A1 (APOA1) is a member of the apolipoprotein family whose members are proteins bind with lipids and form lipoproteins to translate these oil-soluble lipids such as fat and cholesterol through lymphatic and circulatory system. APOA1 is the main component of high density lipoprotein (HDL) in plasma and is involved in the esterification of cholesterol as a cofactor of lecithin-cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters, and thus play a major role in cholesterol efflux from peripheral cells. As a major component of the HDL complex, APOA1 helps to clear cholesterol from arteries. APOA1 is also characterized as a prostacyclin stabilizing factor, and thus may have an anticlotting effect. Defects in encoding gene may result in HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. Men carrying a mutation may develop premature coronary artery disease.
Description A DNA sequence encoding the mouse ApoA1 (Q00623) (Met1-Gln264) was expressed with a C-terminal His tag.
Source HEK293
Predicted N Terminal Trp 19
AA Sequence Met1-Gln264
Molecular Weight The recombinant mouse ApoA1 comprises 257 a.a. and has a predicted molecular mass of 30.2 kDa. The apparent molecular mass of the protein is approximately 27-31 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Purity >94% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
Subcellular Location Secreted.
Protein Families Apolipoprotein A1/A4/E family
Database References
Tissue Specificity Major protein of plasma HDL, also found in chylomicrons.

Gene Functions References

  1. Altered intestinal lymphatic HDL-ApoA-I and miR-223 metabolism in IR and modulation by niacin may provide insight into the intestinal-mediated regulation of the reverse cholesterol transport pathway PMID: 29183962
  2. We developed a chimaeric molecule termed Fibapo in which FGF19 is covalently coupled to apolipoprotein A-I. Fibapo retains FGF19 biological activities but has significantly increased half-life and hepatotropism. Here we evaluated the pro-regenerative activity of Fibapo in two clinically relevant models where liver regeneration may be impaired: acetaminophen (APAP) poisoning, and PH in aged mice. PMID: 28981086
  3. this study indicates that ionic interactions in the C-terminal domain of apoA-I favor self-association and that monomeric apoA-I is more active in solubilizing phospholipid bilayers. PMID: 29578333
  4. These results suggested that apoA-I overexpression could reduce steatosis by decreasing lipid levels and by suppressing endoplasmic reticulum stress and lipogenesis in hepatocytes. ApoA-I expression could significantly reduce hepatic ER stress and lipogenesis in hepatocytes. PMID: 28577569
  5. ABCA1-derived nascent high-density lipoprotein-apolipoprotein AI and lipids metabolically segregate. PMID: 29074589
  6. apoA-I/ABCA1-mediated cholesterol efflux without STAT3 activation can reduce proinflammatory cytokine expression in macrophages. PMID: 26989082
  7. a novel protective role for ApoA-I in colitis and CAC PMID: 26279300
  8. Our results assign a novel role for 4F(apoA-I mimetic peptide ) as a modulator of the TICE pathway and suggest that the anti-inflammatory functions of 4F may be a partial consequence of the codependent intestinal transport of both 4F and cholesterol. PMID: 27199144
  9. Preincubation of endothelial cells with apoA-I protected against the TNF-alpha-induced inhibition of HTR-8/SVneo (trophoblast) cell integration into endothelial (UtMVEC) networks. These data suggest that a healthy lipid profile may affect pregnancy outcomes by priming endothelial cells in preparation for trophoblast invasion. PMID: 27806983
  10. Reductions in Dio1 expression reduce the expression of ApoA-I in a 3,5,3'-triiodothyronine-/thyroid hormone response element-independent manner. PMID: 27150392
  11. apoA-1 deficiency generates changes in the bone cell precursor population that increase adipoblast, and decrease osteoblast production resulting in reduced bone mass and impaired bone quality PMID: 27088511
  12. This study suggests that enhancement of macrophage cholesterol metabolism by PPARgammais not contributed by activating ABCA1 expression and ABCA1-mediated cholesterol efflux to apoAI, which is not involved by CD36 expression either. PMID: 27890613
  13. Mass spectrometry analysis of peptides derived from chemically crosslinked HDL-SAA particles detected multiple crosslinks between apoA1 and SAA, indicating close proximity (within 25 A) of these two proteins on the HDL surface, providing a molecular and structural mechanism for the simultaneous binding of heparin to apoA1 and SAA. PMID: 27105909
  14. results demonstrate that double deletion of Apoe and Apoa1 ameliorated the amyloid pathology. PMID: 26510953
  15. study suggests that apolipoprotein a1 can alleviate obesity related metabolic disease by inducing AMPK dependent mitochondrial biogenesis. PMID: 25982508
  16. ApoA-I can attenuate lymphocyte activation and autoimmunity in Lupus independently of cholesterol transport, through oxidized fatty acid peroxisome proliferator-activated receptor gamma ligands, and it can reduce renal inflammation in glomerulonephritis. PMID: 26466956
  17. KLF14 regulates plasma HDL-C levels and cholesterol efflux capacity by modulating hepatic ApoA-I production. PMID: 26368306
  18. Akt, through its downstream targets, mTORC1 and hence autophagy, negatively regulates cholesterol efflux to apoA-I. PMID: 25415591
  19. macrophage apoAI expression protects against atherosclerosis and dermatitis by reducing cholesterol accumulation and regulating CD4(+) T-cell levels, without affecting serum HDL or tissue macrophage levels. PMID: 25593328
  20. HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function. PMID: 25561462
  21. ApoA1 levels were not associated with AngII-induced abdominal aortic aneurysms in mice. PMID: 26044581
  22. decreased ApoAI synthesis might be accounted for the lower plasma HDL level in ApoCIII transgenic mice PMID: 25969427
  23. MMP-8-deficient mice had significantly lower serum triglyceride (TG) levels (P = 0.003) and larger HDL particles compared with wild-type (WT) mice. However, no differences were observed in the apoA-I levels. PMID: 25550459
  24. Neutrophil recruitment and the neutrophil cytokines, CXCL1/CXCL2, were suppressed in apo(a)transgenic mice in the abdominal aortic aneurysm model. PMID: 24650562
  25. Expression of apoA-I or ABCA1 can reduce steatosis by decreasing lipid storage in hepatocytes through lipid transport and may also reduce endoplasmic reticulum stress, further lessening hepatic steatosis PMID: 24219083
  26. Data from studies in knockout mice suggest that low apoA1 (and thus low HDL) decreases coenzyme Q10 pool, which in turn decreases electron transfer from electron transport complexes II/III in myocardium mitochondria. PMID: 24759932
  27. role of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL PMID: 24123812
  28. the alteration of the hydrophobic 218-222 residues of apoA-I disrupts apoA-I/ABCA1 interactions and promotes the generation of defective pre-beta particles that fail to mature into alpha-HDL subpopulations PMID: 23990662
  29. study identifies a previously unknown proteolytic activity of PLA2 that is specific to apoA-I and may contribute to the enhanced catabolism of apoA-I in inflammation and atherosclerosis. PMID: 24523407
  30. Myeloperoxidase-mediated oxidation renders ApoA-I dysfunctional and unable to promote reverse cholesterol transport, mediate beneficial changes in the composition of atherosclerotic plaques, and pacify the inflammatory status of plaque macrophages. PMID: 24407029
  31. DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels. PMID: 23920041
  32. In the C57BL/6 context, but not FVB/N, apoA-I decreases inflammatory macrophage recruitment and monocytosis, contributors to lesion formation PMID: 24334873
  33. ApoA1 enhances resolution of allergen-induced airway inflammation through promoting recovery of damaged TJs in the bronchial epithelium. PMID: 23889245
  34. This study reveals a potent immunomodulatory role for apoA1 in the tumor microenvironment. PMID: 23720750
  35. ApoA-I Helsinki promotes accumulation of ACAT1 in a mouse macrophage cell line. PMID: 23456478
  36. Data indicate that in contrast to apoA-I-knock-out (KO) mice, apoA-I transgenic mice were moderately resistant to cecal ligation and puncture (CLP)-induced septic death. PMID: 23658016
  37. Apo (a) could attenuate the adhesion, migration, and homing abilities of endothelial progenitor cells(EPCs) and could impair the angiogenesis ability of EPCs. PMID: 23581552
  38. Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice. PMID: 23429073
  39. Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion. PMID: 23322769
  40. Mouse apoA-I, which has a relatively polar C-terminal domain, binds to human high-density lipoprotein to approximately half the level of human apoA-I. PMID: 23425306
  41. the involvement of apoA-I in diet-induced The accumulation of triglycerides in hepatocytes and its potential role in the treatment of nonalcoholic fatty liver disease, is reported. PMID: 22576368
  42. Reduced biliary sterol output with no change in total faecal excretion was found in mice expressing a human apolipoprotein A-I variant. PMID: 22845860
  43. A de novo, loss-of-function mutation in the ApoA1 gene of the BcA68 strain prematurely truncates the ApoA1 protein and is associated with a deviant HDLc plasma level. PMID: 22805347
  44. OVA-challenged apoA-I(-/-) mice exhibited a phenotype of increased airway neutrophils compared with WT mice. PMID: 22427535
  45. fed pregnant mice, with or without a deficiency of Mthfr, choline-deficient diets and examined levels of ApoAI, PPARalpha, IFNgamma, and IL-10. ApoAI mRNA was reduced in Mthfr(+/-) and ApoAI protein was reduced due to Mthfr deficiency or choline deficiency. PMID: 22259189
  46. naturally occuring polymorphisms significantly alter the protein self-association properties, the ability of the proteins to clear lipid micelles from solution, and their binding affinity for mature mouse HDL PMID: 22402133
  47. The FGF19 effect on APOA was attenuated by transfection of primary hepatocytes with siRNA against the FGF19 receptor 4 (FGFR4). PMID: 22267484
  48. Data show that cells expressing Cav1 have 2.6-fold more apoA-I binding sites than Cav1(-/-) cells although these additional binding sites are not associated with detergent-free lipid rafts. PMID: 21858084
  49. the role of the PCPE2 protein in an in vivo model PMID: 21771977
  50. analysis of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano) PMID: 19120689


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed